Knowmade 2
mRNA Cancer Therapies Patent Landscape 2022: Featuring BioNTech, Moderna, Novartis, Sanofi & Others
04 oct. 2022 04h03 HE | Research and Markets
Dublin, Oct. 04, 2022 (GLOBE NEWSWIRE) -- The "mRNA Cancer Therapies Patent Landscape 2022" report has been added to's offering. For nearly three decades, extensive efforts...
Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC)
13 janv. 2022 07h00 HE | Gritstone bio
-- Phase 2/3 GRANITE-CRC-1L trial has registrational intent -- -- Updated data from Phase 1/2 trial in end-stage metastatic MSS-CRC further support the association of circulating tumor DNA (ctDNA)...
Achilles Therapeutics Logo RGB Small.jpg
Achilles Therapeutics Presents Data at the 2021 European Society for Gene and Cell Therapy (ESGCT) Congress Demonstrating its Proprietary Manufacturing Process Can Generate Potent, Personalized Anti-Cancer Cell Therapy Candidates in Multiple Solid Tumor Types
22 oct. 2021 07h30 HE | Achilles Therapeutics PLC
LONDON, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...